Early Experience with the Latest-Generation Biological Prosthesis, the Trifecta™ GT.

Background: The study aim was to assess the hemodynamic results and implantation technique for the latest-generation St. Jude Medical aortic valve bioprosthesis, the Trifecta™ GT, which was first marketed in 2016.

Methods: The first 100 patients (mean age 74.

The 3f Enable sutureless bioprosthesis: Early results, safeguards, and pitfalls.

Objective: The aim of the study was to evaluate the clinical and hemodynamic performance of the 3f Enable (Medtronic Inc, Minneapolis, Minn) sutureless bioprosthesis in the early postoperative period. Its implantation technique was also evaluated highlighting the modifications in regard to the original technique and mistakes made throughout the learning curve.

Methods: This is a prospective, nonrandomized study.

St. Jude Medical Trifecta™ aortic valve perioperative performance in 200 patients.

Objectives: The St. Jude Medical Trifecta aortic bioprosthesis (St. Jude Medical, Inc.